The TDR Tuberculosis Strain Bank: A resource for basic science, tool development and diagnostic services

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 1, 2012, Pages 24-31

  Vincent, V ^a,b   Rigouts, Leen ^c   Nduwamahoro, E ^c   Holmes, B ^d   Cunningham, J ^a   Guillerm, M ^a   Nathanson, C M ^a   Moussy, F ^a   De Jong, B ^c   Portaels, F ^c   Ramsay, A ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b INSTITUT PASTEUR   (France)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d National Collection of Type Cultures   (United Kingdom)

Author keywords

Diagnostics development; Drug susceptibility testing; Mycobacterium tuberculosis; Strain bank

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIUM COLONY; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; EMBB GENE; FREEZE DRYING; GENE LOCUS; GENE MUTATION; GEOGRAPHIC ORIGIN; GYRA GENE; GYRB GENE; HEALTH CARE FACILITY; HUMAN; INHA GENE; INTERSPERSED REPEAT; KATG GENE; MATERIALS HANDLING; MEDICAL RESEARCH; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PRESERVATION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RPOB GENE; RPSL GENE; RRS GENE; SEQUENCE ANALYSIS; STRAIN BANK; SUSPENSION; VARIABLE NUMBER OF TANDEM REPEAT;

ANTITUBERCULAR AGENTS; BIOLOGICAL SPECIMEN BANKS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; PROGRAM DEVELOPMENT; TUBERCULOSIS;

EID: 84555194797     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0223     Document Type: Review

References (15)

1. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
2. World Health Organization. Anti-tuberculous drug resistance in the world. Report no. 4. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
3. Singh J A, Upshur R, Padayatchi N. XDR-TB in South Africa: no time for denial or complacency. PLoS Med 2007; 4: e50.
4. Shah N S, Wright A, Bai G-H, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-387. (Pubitemid 46348124)
5. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-650. (Pubitemid 23083244)
6. Nathanson C-M, Cuevas L E, Cunningham J, et al. The TDR Tuberculosis Specimen Bank: a resource for diagnostic test developers. Int J Tuberc Lung Dis 2010; 14: 1461-1467.
7. World Health Organization. Policy guidance on drugs-usceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008.392. Geneva, Switzerland: WHO, 2008.
8. Supply P, Allix C, Lesjean S, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 4498-4510. (Pubitemid 44937085)
9. Supply P, Mazars E, Lesjean S, Vincent V, Gicquel B, Locht C. Variable human minisatellite-like regions in the Mycobacterium tuberculosis genome. Mol Microbiol 2000; 36: 762-771. (Pubitemid 30258858)
10. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907-914. (Pubitemid 27146535)
11. Van Deun A, Barrera L, Bastian I, et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009; 47: 3501-3506.
12. International Society for Biological and Environmental Repositories. 2008 best practices for repositories. Collection, storage, retrieval and distribution of biological materials for research. Bethesda, MD, USA: ISBER, 2008.
13. World Health Organization. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD global project on antituberculosis drug resistance surveillance. WHO/TB/97.229. Geneva, Switzerland: WHO, 1997.
14. Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010; 48: 2495-2501.
15. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010; 48: 229-237.